)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Biomea Fusion
Biomea Fusion (BMEA) investor relations material
Biomea Fusion Oppenheimer 36th Annual Healthcare Life Sciences Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Oppenheimer 36th Annual Healthcare Life Sciences Conference summary26 Feb, 2026
Pipeline overview and clinical strategy
Two oral small molecule candidates are in development: Icovamenib for diabetes and BMF-650 for weight loss/obesity.
Icovamenib targets insulin-deficient and GLP-1 inadequately controlled type 2 diabetes, with two phase II trials (COVALENT-211 and COVALENT-212) underway.
BMF-650, an oral GLP-1 receptor agonist, is being developed for weight loss with a favorable safety and pharmacokinetic profile.
Key clinical catalysts include primary endpoint data for Icovamenib studies in Q4 2026 and mid-year or Q2 2026 weight loss data for BMF-650.
The company retains full worldwide rights across all programs.
Clinical data and mechanism of action
Icovamenib showed sustained A1C/HbA1c reduction for up to nine months post-treatment in insulin-deficient patients.
The drug acts as a menin inhibitor, promoting beta cell proliferation and increased insulin production.
Enhanced GLP-1 receptor and insulin expression was observed, with potential synergy when combined with semaglutide.
Similar A1C improvements were seen in patients failing GLP-1 therapy, with increased endogenous insulin measured by C-peptide.
BMF-650 demonstrated robust, dose-dependent weight loss in preclinical models.
Patient selection and trial design
Patient selection for Icovamenib trials is based on A1C (7.5–10.5), BMI (<32), and failure of 1–3 prior medications.
Inclusion criteria focus on adults with type 2 diabetes not achieving glycemic targets, with background therapy maintained unless rescue is required.
Two phase II studies: COVALENT-211 for insulin-deficient patients and COVALENT-212 for those failing GLP-1 therapy.
Trials maintain background therapy to isolate Icovamenib's effect, with primary endpoints at 26 weeks and secondary at 52 weeks.
Enrollment for the 211 study is expected to be completed in four months, with primary endpoint data by year-end.
Icovamenib: Commercial patient identification?
Icovamenib: Phase 2 trial design and path to P3?
BMF-650: Oral GLP-1 differentiation strategy?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Next Biomea Fusion earnings date
The Citizens Life Sciences Conference 202610 Mar, 2026
Biomea Fusion
Next Biomea Fusion earnings date
The Citizens Life Sciences Conference 202610 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Biomea Fusion Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery and development of covalent small molecule drugs. These drugs are designed to treat patients with genetically defined cancers and metabolic diseases. The company’s approach leverages covalent bonding, where a small molecule forms a permanent bond with its target protein, which may offer advantages like greater target selectivity and a more durable therapeutic response. The company is headquartered in Redwood City, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage